180 Life Sciences Corp.
Index- P/E- EPS (ttm)-0.75 Insider Own12.20% Shs Outstand29.76M Perf Week36.19%
Market Cap42.56M Forward P/E- EPS next Y-0.52 Insider Trans3.49% Shs Float22.07M Perf Month-21.86%
Income-20.30M PEG- EPS next Q-0.13 Inst Own9.40% Short Float6.02% Perf Quarter-58.91%
Sales- P/S- EPS this Y2.00% Inst Trans-1.27% Short Ratio3.30 Perf Half Y-64.60%
Book/sh1.16 P/B1.23 EPS next Y32.10% ROA-33.30% Target Price5.00 Perf Year-80.88%
Cash/sh0.28 P/C5.19 EPS next 5Y- ROE-79.80% 52W Range1.00 - 11.75 Perf YTD-63.33%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-87.83% Beta0.03
Dividend %- Quick Ratio0.60 Sales past 5Y- Gross Margin- 52W Low43.00% ATR0.20
Employees7 Current Ratio0.60 Sales Q/Q- Oper. Margin- RSI (14)44.76 Volatility15.37% 15.27%
OptionableYes Debt/Eq0.05 EPS Q/Q118.40% Profit Margin- Rel Volume0.59 Prev Close1.26
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume403.13K Price1.43
Recom2.00 SMA20-1.79% SMA50-32.12% SMA200-64.61% Volume237,229 Change13.49%
Sep-15-21Initiated Maxim Group Buy $11
May-02-22 08:00AM  
Apr-29-22 06:32PM  
Feb-17-22 08:30AM  
Jan-31-22 08:00AM  
Dec-28-21 11:00AM  
Dec-15-21 08:15AM  
Dec-12-21 06:06AM  
Dec-10-21 05:15PM  
Dec-06-21 08:15AM  
Dec-01-21 02:45PM  
Nov-22-21 08:30AM  
Nov-18-21 08:15AM  
Nov-03-21 12:06PM  
Oct-26-21 08:30AM  
Sep-30-21 08:30AM  
Sep-20-21 08:00AM  
Aug-30-21 08:30AM  
Aug-24-21 08:30AM  
Aug-19-21 09:00AM  
Aug-02-21 08:00AM  
Jul-29-21 08:00AM  
Jul-28-21 08:15AM  
Jul-20-21 08:00AM  
Jul-12-21 09:51AM  
Jul-07-21 08:00AM  
Jun-28-21 08:15AM  
Jun-10-21 09:12AM  
Jun-01-21 08:00AM  
May-28-21 08:00AM  
May-21-21 04:45PM  
Apr-20-21 08:00AM  
Apr-19-21 05:00PM  
Apr-14-21 08:15AM  
Mar-26-21 08:30AM  
Mar-25-21 08:30AM  
Mar-24-21 08:30AM  
Mar-08-21 01:30PM  
Feb-24-21 04:00PM  
Feb-19-21 09:00AM  
Feb-17-21 12:00AM  
Jan-11-21 08:00AM  
Jan-05-21 02:50PM  
Dec-03-20 11:08AM  
Nov-24-20 10:00AM  
Nov-23-20 08:30AM  
Nov-17-20 08:00AM  
Nov-10-20 11:46AM  
180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Vu Quan AnhCOO / Chief Business OfficerDec 16Buy3.988,00031,84020,500Dec 16 05:00 PM
Pamir OzanInterim CFODec 10Buy3.873,80014,70676,408Dec 13 08:31 AM
Marrone Pamela GDirectorDec 10Buy4.101,0004,1001,000Dec 10 06:39 PM
Vu Quan AnhCOO / Chief Business OfficerDec 10Buy3.904,50017,55012,500Dec 10 06:04 PM
McGovern Jr. Donald A.DirectorDec 09Buy4.1325,000103,25032,628Dec 09 09:58 PM
Woody James N.Chief Executive OfficerDec 09Buy4.2712,50053,37537,752Dec 10 08:24 AM
STEINMAN LAWRENCEDirectorDec 09Buy4.275,00021,350602,574Dec 10 08:22 AM
Feldmann MarcDirectorDec 09Buy4.0750,000203,5002,809,930Dec 13 04:18 PM
DeLuca TeresaDirectorDec 09Buy3.977,50029,8002,500Dec 13 08:35 AM
DeLuca TeresaDirectorDec 09Buy4.005,00020,0005,000Dec 13 08:35 AM